ABSTRACT
A recently described, rare genetic condition known as Neurodevelopmental Disorder with Microcephaly, Arthrogryposis, and Structural Brain Anomalies (NEDMABA) has been identified in children with bi-allelic loss-of-function variants in SMPD4. The progression of this condition is not well understood with the limited case reports described so far exhibiting a severe and clinically diverse phenotype. A gap exists in the understanding of associations present in the heterogenous features of the clinical phenotype, and the expected survival probabilities of affected individuals. This is driven in part to the paucity of analysis-ready data on reported cases. This analysis aims to collate and standardise available case reports into a common dataset, to analyse and identify meaningful clusters in the clinical phenotype, and to quantify the survival probability for children with NEDMABA. To overcome the challenge of multidimensional data on very few subjects, we employ Multiple Correspondence Analysis (MCA) as a dimension reduction technique, which is then subject to cluster analysis and interpretation. To account for censoring in the data, Kaplan-Meier estimation is formulated to calculate patient survival time. The analysis correctly detected the classic phenotype for this condition, as well as a new distinct feature-cluster relating to findings of vocal cord paralysis, feeding dysfunction and respiratory failure. The survival probability for those affected was found to decline sharply in early infancy with median survival of 150 days, but with some surviving as long as 12.5 years. This wide range of outcomes is provisionally associated with different variant types however this conclusion could not be validated based on very low sample sizes. An R package called SMPD4 was developed to publish standardised analysis-ready datasets used in this study. This analysis represents the first of its kind to help describe associations and trajectories of individuals with this newly reported condition, despite challenges with sparse and inconsistent data. This analysis can provide clinicians and genetic counsellors with better information to aide in decision making and support for families with this rare condition.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is a meta analysis. The study used (or will use) ONLY openly available human data that were originally located at: Bijarnia-Mahay, S. et al. (2022). Growth and neurodevelopmental disorder with arthrogryposis, microcephaly and structural brain anomalies caused by Bi-allelic partial deletion of SMPD4 gene. Journal of human genetics, 67(3), 133-136. https://doi.org/10.1038%2Fs10038-021-00981-3 Magini, P. et al. (2019). Loss of SMPD4 causes a developmental disorder characterized by microcephaly and congenital arthrogryposis. The American Journal of Human Genetics, 105(4), 689-705. https://doi.org/10.1016/j.ajhg.2019.08.006 Ji, W. et al.(2022). Case Report: Novel Biallelic Null Variants of SMPD4 Confirm Its Involvement in Neurodevelopmental Disorder With Microcephaly, Arthrogryposis, and Structural Brain Anomalies. Frontiers in Genetics, 13. https://doi.org/10.3389%2Ffgene.2022.872264 Ravenscroft, G. et al. (2021). Neurogenetic fetal akinesia and arthrogryposis: genetics, expanding genotype-phenotypes and functional genomics. Journal of medical genetics, 58(9), 609-618. https://doi.org/10.1136%2Fjmedgenet-2020-106901 Monies, D. et al. (2019). Lessons learned from large-scale, first-tier clinical exome sequencing in a highly consanguineous population. The American Journal of Human Genetics,104(6), 1182-1201. https://doi.org/10.1016%2Fj.ajhg.2019.04.011
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced are available online at https://doi.org/10.5281/zenodo.7071092
